Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Anacor Pharmaceuticals Inc    ANAC   US0324201013

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/26/2015 01/27/2015 01/28/2015 01/29/2015 01/30/2015 Date
36.62(c) 36.79(c) 37.05(c) 38.56(c) 37.6(c) Last
641 115 617 868 550 823 253 449 509 521 Volume
+7.23% +0.46% +0.71% +4.08% -2.49% Change
More quotes
Company
Anacor Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.The company has discovered seven compounds that are currently in development including its lead... 
More about the company
Surperformance© ratings of Anacor Pharmaceuticals Inc
Trading Rating : Investor Rating :
More Ratings
Chart ANACOR PHARMACEUTICALS INC
Duration : Period :
Anacor Pharmaceuticals Inc Technical Analysis Chart | ANAC | US0324201013 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 15,8 M
EBIT 2014 -93,9 M
Net income 2014 -98,4 M
Debt 2014 25,7 M
Yield 2014 -
Sales 2015 38,5 M
EBIT 2015 -74,9 M
Net income 2015 -75,4 M
Debt 2015 61,3 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 104x
EV / Sales 2015 43,5x
Capitalization 1 613 M
More Financials
Latest news on ANACOR PHARMACEUTICALS INC
01/12 ANACOR PHARMACEUTICALS : Entry into a Material Definitive Agreement, Regulation ..
01/07 ANACOR PHARMACEUTICALS : Symbiota : Names Entrepreneurial Leader David P. Perry ..
2014 ANACOR PHARMACEUTICALS : Assigned Patent
2014 ANACOR PHARMACEUTICALS : U.S. Patents Awarded to Inventors in Pennsylvania (Nov...
2014 ANACOR PHARMACEUTICALS : U.S. Patents Awarded to Inventors in Ohio (Nov. 24)
2014 ANACOR PHARMACEUTICALS : Assigned Patent
2014 ANACOR PHARMACEUTICALS : to Take Part in the 2014 Credit Suisse Healthcare Confe..
2014 ANACOR PHARMACEUTICALS : Reports Third Quarter 2014 Financial Results
More news
Sector news Biotechnology & Medical Research - NEC
01/30 PHARMACYCLICS : Johnson & Johnson: U.S. FDA Approves IMBRUVICA (ibrutinib) for t..
01/29DJValeant to Buy Prostate-Cancer Drug From Dendreon
01/29DJValeant in Deal to Buy Prostate-Cancer Drug Provenge From Dendreon
Plus d'actualités du secteur Biotechnology & Medical Research - NEC


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF